A 52-week randomized,double-blind, placebocontrolled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L antagonist monoclonal antibody, for preservation of pancreatic ß-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

• Protocol code: DRI17476
• EudraCT code: No aplica
• Research group: Diabetes and Metabolism
• Service: Endocrinology
• Principal investigator:  Hernández Pascual, Cristina
• Pathology: Malalties endocrines, nutricionals i metabòliques
• Phase: Fase II